Pamela M. Klein, MD

Dr. Pamela Klein is a medical oncologist and biotechnology executive with 20 years of experience in drug development. She is Founder of PMK BioResearch, offering advisory and strategic consulting for the biotechnology industry and venture firms. She is a member of the Board of Directors of Argenx, Patrys, Frontiers Medicines and I-Mab Biopharma as well as a member of several Scientific Advisory Boards. Dr. Klein has held the role of CMO at multiple companies including Olema Oncology and Intellikine (acquired by Takeda). From 2001-2008, Dr. Klein held increasing positions of responsibility at Genentech ending with Vice President, Development, where she led the development of a portfolio of drugs including Herceptin®, Rituxan®, Perjeta®, and Tarceva®. Prior to Genetech, Dr. Klein was Research Director for the National Cancer Institute-Navy Breast Care Center which she co-founded and led until leaving the NCI.